Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 22, 2005. The report serves as a notification of transactions involving directors or persons discharging managerial responsibility, specifically detailing a decrease in shareholdings.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding insider trading activity rather than a financial performance report.
Material Changes
The only material change disclosed is a decrease in the personal holdings of Ordinary Shares ADRs by Mr. R Greig. The transaction involved the sale of ADRs on August 15, 2005, at a price of $47.97 per ADR.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly adheres to Disclosure Rule 3.1.4R(1)(a) regarding the notification of the director's transaction.
Investor Verification Points
- Verify the exact number of ADRs sold by Mr. R Greig, as the filing mentions the price ($47.97) but omits the specific volume in the provided text.
- Confirm the current total shareholding of Mr. R Greig post-transaction to assess remaining exposure.
- Check subsequent filings for any related financial performance data, as this 6-K does not contain operational metrics.